Species distribution and antifungal sensitivity patterns of vaginal yeasts.
OBJECTIVE
To identify yeastisolates in vaginal specimens to species level and determine their antifungal susceptibility patterns.


METHODS
Cross-sectional laboratory-based study.


METHODS
The Aga Khan University Hospital (AKUH), Nairobi.


METHODS
Yeast isolates from high vaginal swabs presented to the laboratory for culture and sensitivity were identified to species level using the API Candida system and subjected to broth microdilution susceptibility testing.


METHODS
Frequency tables and graphs were used to summarise the data. Susceptibility data was analysed by the non-parametric Fisher's exact test. P < 0.05 was considered statistically significant.


RESULTS
A total of 101 yeasts were studied. C. albicans was the prominent species (69.3%) followed by C. glabrata (12.9%), C. famata (5.0%), C. krusei (3.0%), Trichosporon species (3.0%) and S.cerevisiae (3.0%), C.parapsilosis (1.0%). Three (3.0%) of the isolates had profiles that fell between C. glabrata and C. famata. The percentages of C. albicans susceptible to flucytosine, amphotericin B, fluconazole and itraconazole were 94.3, 92.9, 100 and 90 respectively; that of non-albicans isolates were 93.5, 80.6, 77.4 and 29 respectively. There was no significant difference (p > 0.05) between the susceptibility of C. albicans and non-albicans isolates to flucytosine and amphotericin B, however there was a significant difference (p < 0.05) to fluconazole and itraconazole.


CONCLUSIONS
C. albicans was the predominant cause of vulvovaginal candidiasis in this study, and demonstrated good susceptibility to antifungal agents tested. A significant number of non-albicans yeasts were identified; these demonstrated reduced susceptibility to all drugs, in particular to the azoles which are commonly used for treatment of vaginal candidiasis. The isolation of non-albicans yeasts may have clinical implication given their reduced susceptibility to antifungals.
Department of Medical Microbiology, College of Health Sciences, University of Nairobi, P.O. Box 19676-00202, Nairobi, Kenya.
F
F
Mutua
G
G
Revathi
J M
JM
Machoki
D000935:Antifungal Agents / Q000494:pharmacology*; D002175:Candida / Q000187:drug effects* / Q000302:isolation & purification*; D002181:Candidiasis, Vulvovaginal / Q000382:microbiology*; D003430:Cross-Sectional Studies; D025141:Drug Resistance, Fungal; D005260:Female; D006801:Humans; D007630:Kenya; D008826:Microbial Sensitivity Tests
D000935:Antifungal Agents